Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane Oxygenation
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Colistin is a lipopeptide antibiotic administered as an inactive prodrug - colistin
methanesulfonate (CMS). Colistin is a drug with a narrow therapeutic window; the limiting
factors are mainly nephrotoxicity and neurotoxicity dependent on plasma concentrations. The
number of patients with these types of infections, as well as the number of patients
requiring extracorporeal membrane oxygenation (ECMO) support for severe respiratory failure,
increased significantly in association with COVID-19-induced infections. ECMO can generally
affect the pharmacokinetics of drugs by creating a new compartment.
Phase:
Phase 4
Details
Lead Sponsor:
St. Anne's University Hospital Brno, Czech Republic